What did @beauty_by_joanne_ actually say?
Joanne is returning to Mounjaro (tirzepatide) after a six-week break and says she's been using MedExpress as her supplier. Her complaint isn't about the drug itself. It's about fulfilment. She says deliveries have arrived with missing components, specifically "Swellbout" (almost certainly "swabs") and needles. She's asking her audience where else they're sourcing their Mounjaro and what it's costing them, framing this as a consumer comparison exercise rather than a medical one.
To be clear about what she's actually doing here: she's crowdsourcing telehealth provider recommendations on TikTok, which is a genuinely risky approach to managing a prescription medication. She's not making clinical claims. She's not claiming the drug cures anything. But the framing, treating GLP-1 medication suppliers like Amazon sellers you can switch between, carries its own set of problems worth addressing.
Does the science back this up?
There's no clinical claim to evaluate here in the traditional sense. Joanne isn't making a pharmacological argument. But her experience of stopping and restarting tirzepatide after six weeks is clinically relevant, and the research on that is fairly clear-cut.
Stopping GLP-1 receptor agonists typically leads to weight regain. A 2022 study published in Diabetes, Obesity and Metabolism (Wilding et al.) found that participants who discontinued semaglutide regained approximately two-thirds of their lost weight within a year. Tirzepatide data from the SURMOUNT-4 trial (Aronne et al., 2024, JAMA) confirmed a similar pattern: those who switched to placebo after 36 weeks of tirzepatide regained significant weight, while those who continued lost more. Six weeks off is long enough to matter biologically. Appetite regulation, gastric emptying rates, and satiety signalling are all affected by cessation.
So her plan to get back on it is consistent with what the evidence says about long-term use. The problem is the way she's going about sourcing it.
What did they get wrong (or right)?
She's right that fulfilment quality matters. Missing injection supplies, whether swabs or needles, isn't a trivial complaint. Administering subcutaneous injections without proper sterile technique is a genuine safety issue, not a customer service grievance. If a regulated provider is shipping incomplete kits, that's worth raising formally, not just venting about on TikTok.
Where this gets complicated is the call to "hit me up" for alternative supplier recommendations. The UK market for compounded and imported tirzepatide is not uniform. Some providers operate under proper MHRA-registered frameworks. Others operate in murkier territory. Switching providers based on TikTok recommendations, without verifying prescribing oversight, consultation quality, or product provenance, is a real risk. She actually acknowledges MedExpress's consultation and check-in process is "really good." That matters more than she seems to realise. Regulatory oversight and clinical follow-up are not optional extras when you're on a weekly injectable medication that affects heart rate, gastrointestinal function, and thyroid markers.
There's also nothing here about what dose she was on before or whether restarting at the same dose is appropriate after a six-week gap. Clinicians typically recommend retitrating after breaks of this length.
What should you actually know?
If you're on tirzepatide or semaglutide in the UK and considering switching providers, the question isn't just price or delivery speed. It's whether the provider is registered with the Care Quality Commission, whether prescriptions are issued by a UK-registered prescriber, and whether the product comes from a licensed pharmacy. Compounded tirzepatide and branded Mounjaro are not the same product, and any provider suggesting otherwise is misrepresenting the regulatory position.
Missing kit components should be reported to the provider directly and, if unresolved, to the MHRA or CQC. That's not being difficult. That's how regulated healthcare is supposed to work.
Restarting GLP-1 therapy after a break is something to do with clinical input, not something to crowdsource. A prescriber should be confirming whether retitration is needed, reviewing any changes in your health status during the break, and monitoring for side effects on restart. The drug is effective. The evidence is solid. But "effective" and "safe without oversight" are not the same thing.